[{"address1": "108 Patriot Drive", "address2": "Suite A", "city": "Middletown", "state": "DE", "zip": "19709", "country": "United States", "phone": "302 274 8744", "website": "https://www.zymeworks.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.", "fullTimeEmployees": 290, "companyOfficers": [{"maxAge": 1, "name": "Mr. Kenneth H. Galbraith C.A.", "age": 60, "title": "Chairman, CEO & Interim CFO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1036249, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Paul  Moore Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 872666, "exercisedValue": 0, "unexercisedValue": 342750}, {"maxAge": 1, "name": "Mr. Mark  Hollywood", "age": 53, "title": "Executive VP and Head of Technical & Manufacturing Operations", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Dex J.D., Ph.D.", "title": "Senior VP, Corporate Secretary & General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Diana  Papove", "title": "Senior Manager of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lindsey  Foulkes B.Sc., Ph.D.", "title": "Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Laura  O'Connor", "title": "Vice President of Human Resources & DEI", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey  Smith M.D.", "title": "Executive VP & Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Josemund  Menezes MBBS", "title": "Managing Director of Early-Stage Development for Asia Pacific", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Fann Ph.D.", "title": "Senior Vice President of Process Sciences", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.59, "open": 11.68, "dayLow": 11.51, "dayHigh": 11.88, "regularMarketPreviousClose": 11.59, "regularMarketOpen": 11.68, "regularMarketDayLow": 11.51, "regularMarketDayHigh": 11.88, "beta": 1.19, "forwardPE": -10.137932, "volume": 341949, "regularMarketVolume": 341949, "averageVolume": 677588, "averageVolume10days": 772780, "averageDailyVolume10Day": 772780, "bid": 11.75, "ask": 11.8, "bidSize": 100, "askSize": 200, "marketCap": 835517440, "fiftyTwoWeekLow": 6.015, "fiftyTwoWeekHigh": 13.14, "priceToSalesTrailing12Months": 13.324574, "fiftyDayAverage": 10.1608, "twoHundredDayAverage": 9.9344, "currency": "USD", "enterpriseValue": 513381248, "profitMargins": -1.79424, "floatShares": 39446221, "sharesOutstanding": 71047400, "sharesShort": 3730010, "sharesShortPriorMonth": 3671159, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0525, "heldPercentInsiders": 0.040110003, "heldPercentInstitutions": 0.98605, "shortRatio": 4.99, "shortPercentOfFloat": 0.0596, "bookValue": 5.734, "priceToBook": 2.0509243, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -112508000, "trailingEps": -1.5, "forwardEps": -1.16, "pegRatio": -0.96, "enterpriseToRevenue": 8.187, "enterpriseToEbitda": -4.443, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ZYME", "underlyingSymbol": "ZYME", "shortName": "Zymeworks Inc.", "longName": "Zymeworks Inc.", "firstTradeDateEpochUtc": 1493386200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "73a7b41d-8e6f-3fa4-a390-f8202495de01", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.76, "targetHighPrice": 21.0, "targetLowPrice": 10.0, "targetMeanPrice": 14.5, "targetMedianPrice": 14.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 330145984, "totalCashPerShare": 4.647, "ebitda": -115551000, "totalDebt": 20088000, "quickRatio": 6.62, "currentRatio": 7.009, "totalRevenue": 62705000, "debtToEquity": 4.946, "revenuePerShare": 0.853, "returnOnAssets": -0.13622, "returnOnEquity": -0.26315, "freeCashflow": -63659624, "operatingCashflow": -91372000, "revenueGrowth": 1.748, "grossMargins": -0.93367, "ebitdaMargins": -1.84277, "operatingMargins": -1.3303, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]